Investors continue to probe whether AI investment meaningfully changes biotech valuation, according to a new market read on healthcare AI narratives. A review by Fishbone Advisors argues that the AI story is often believed more readily in biotech when it maps to earlier-stage pipeline discovery, while pharma receives higher marks only when AI can tie to measurable financial outcomes. The analysis points to a communication gap: management teams must connect AI-enabled data and modeling work to concrete business milestones, rather than relying on broad claims about “frontier” capabilities. It also suggests smaller biotechs may need to focus on niche dominance rather than platform breadth. Overall, the sentiment implies AI optimism remains, but credibility hinges on return-on-investment discipline and evidence of operational impact.